Ensign Peak Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
Other funds holding HAE
Ensign Peak Advisors's HAE Position: Q3 2026 in Review
Ensign Peak Advisors reduced its Haemonetics (HAE) stake by 17% in Q3 2026, selling an estimated $51.2K and leaving 2,616 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #1154.
Ensign Peak Advisors first reported a position in HAE in Q4 2019 and has held it in 28 quarters since. The position peaked at $6.1M in Q4 2020. 361 funds tracked by Wall St. Rank hold HAE as of Q3 2026.
- Ensign Peak Advisors held 2,616 shares of Haemonetics worth $275K as of Q3 2026.
- Ensign Peak Advisors sold 550 Haemonetics shares in Q3 2026, an estimated $51.2K.
- Haemonetics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #1154 holding.
- Ensign Peak Advisors first reported a position in Haemonetics in Q4 2019 and has held it in 28 quarters since.
- Ensign Peak Advisors's Haemonetics position peaked at $6.1M in Q4 2020.
- 361 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.